Kelly M Chin1, Mardi Gomberg-Maitland2, Richard N Channick3, Michael J Cuttica4, Aryeh Fischer5, Robert P Frantz6, Elke Hunsche7, Leah Kleinman8, John W McConnell9, Vallerie V McLaughlin10, Chad E Miller11, Roham T Zamanian12, Michael S Zastrow13, David B Badesch14. 1. University of Texas Southwestern, Internal Medicine, Pulmonary Hypertension Program, Dallas, TX. Electronic address: kelly.chin@utsouthwestern.edu. 2. Inova Heart and Vascular Institute, Falls Church, VA. 3. Massachusetts General Hospital, Boston, MA. 4. Northwestern University, Medicine, Pulmonary and Critical Care Medicine, Chicago, IL. 5. University of Colorado Denver, Medicine, Rheumatology/Pulmonary Sciences & Critical Care Medicine, Aurora, CO. 6. Mayo Clinic Rochester, Rochester, MN. 7. Actelion Pharmaceuticals Ltd, Allschwil, Switzerland. 8. Evidera, Bethesda, MD. 9. Kentuckiana Pulmonary Associates, Louisville, KY. 10. University of Michigan, Cardiovascular Medicine, Ann Arbor, MI. 11. Piedmont Healthcare, Atlanta, GA. 12. Stanford University Medical Center, Pulmonary & Critical Care Medicine, Stanford, CA. 13. Actelion Pharmaceuticals US, Inc, South San Francisco, CA. 14. University of Colorodo Denver, Cardiology/Pulmonary Sciences & Critical Care Medicine, Aurora, CO.
Abstract
BACKGROUND: Disease-specific patient-reported outcome (PRO) instruments are important in assessing the impact of disease and treatment. The Pulmonary Arterial Hypertension-Symptoms and Impact Questionnaire is the first instrument for quantifying pulmonary arterial hypertension (PAH) symptoms and impacts developed according to the 2009 US Food and Drug Administration PRO guidance; previous qualitative research in patients with PAH supported its initial content validity. METHODS: Content finalization and psychometric validation were conducted by using data from A Study of Macitentan in Pulmonary Arterial Hypertension to Validate the PAH-SYMPACT (SYMPHONY), a single-arm, 16-week trial with macitentan 10 mg in US patients with PAH. Item performance, Rasch analysis, and factor analyses were used to select the final item content of the PRO and to define its domain structure. Internal consistency, test-retest reliability, known-group and construct validity, sensitivity to change, and influence of oxygen on item performance were evaluated. RESULTS: Data from 278 patients (79% female; mean age: 60 years) were analyzed. Following removal of redundant/misfitting items, the final questionnaire has 11 symptom items across two domains (cardiopulmonary and cardiovascular symptoms) and 11 impact items across two domains (physical and cognitive/emotional impacts). Differential item function analysis confirmed that PRO scoring is unaffected by oxygen use. For all four domains, internal consistency reliability was high (Cronbach's alpha > 0.80), and scores were highly reproducible in stable patients (intraclass correlation coefficient: 0.84-0.94). Correlations with the Cambridge Pulmonary Hypertension Outcome Review questionnaire and the 36-item Medical Outcomes Study Short Form Survey were moderate to high ([r] = 0.34-0.80). The questionnaire differentiated well between patients with varying disease severity levels and was sensitive to improvements in clinician- and patient-reported disease severity. CONCLUSIONS: The Pulmonary Arterial Hypertension-Symptoms and Impact Questionnaire is a brief, disease-specific PRO instrument possessing good psychometric properties that can be administered in clinical practice and clinical studies. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01841762; URL: www.clinicaltrials.gov.
BACKGROUND: Disease-specific patient-reported outcome (PRO) instruments are important in assessing the impact of disease and treatment. The Pulmonary Arterial Hypertension-Symptoms and Impact Questionnaire is the first instrument for quantifying pulmonary arterial hypertension (PAH) symptoms and impacts developed according to the 2009 US Food and Drug Administration PRO guidance; previous qualitative research in patients with PAH supported its initial content validity. METHODS: Content finalization and psychometric validation were conducted by using data from A Study of Macitentan in Pulmonary Arterial Hypertension to Validate the PAH-SYMPACT (SYMPHONY), a single-arm, 16-week trial with macitentan 10 mg in US patients with PAH. Item performance, Rasch analysis, and factor analyses were used to select the final item content of the PRO and to define its domain structure. Internal consistency, test-retest reliability, known-group and construct validity, sensitivity to change, and influence of oxygen on item performance were evaluated. RESULTS: Data from 278 patients (79% female; mean age: 60 years) were analyzed. Following removal of redundant/misfitting items, the final questionnaire has 11 symptom items across two domains (cardiopulmonary and cardiovascular symptoms) and 11 impact items across two domains (physical and cognitive/emotional impacts). Differential item function analysis confirmed that PRO scoring is unaffected by oxygen use. For all four domains, internal consistency reliability was high (Cronbach's alpha > 0.80), and scores were highly reproducible in stable patients (intraclass correlation coefficient: 0.84-0.94). Correlations with the Cambridge Pulmonary Hypertension Outcome Review questionnaire and the 36-item Medical Outcomes Study Short Form Survey were moderate to high ([r] = 0.34-0.80). The questionnaire differentiated well between patients with varying disease severity levels and was sensitive to improvements in clinician- and patient-reported disease severity. CONCLUSIONS: The Pulmonary Arterial Hypertension-Symptoms and Impact Questionnaire is a brief, disease-specific PRO instrument possessing good psychometric properties that can be administered in clinical practice and clinical studies. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01841762; URL: www.clinicaltrials.gov.
Authors: Hilary M DuBrock; Yogesh N Reddy; Louise A Durst; Darrell R Schroeder; Grace Park; Hector R Cajigas; Garvan C Kane; Sudhir S Kushwaha; Robert B McCully; Joseph G Murphy; Vidhu Anand; Michael J Krowka; Robert P Frantz Journal: Pulm Circ Date: 2022-10-01 Impact factor: 2.886
Authors: Jasleen Minhas; Haochang Shou; Steven Hershman; Roham Zamanian; Corey E Ventetuolo; Todd M Bull; Anna Hemnes; Murali M Chakinala; Stephen Mathai; Nadine Al-Naamani; Susan Ellenberg; Lea Ann Matura; Steven M Kawut; Anna Shcherbina Journal: Ann Am Thorac Soc Date: 2022-04
Authors: Olivier Sitbon; Mardi Gomberg-Maitland; John Granton; Michael I Lewis; Stephen C Mathai; Maurizio Rainisio; Norman L Stockbridge; Martin R Wilkins; Roham T Zamanian; Lewis J Rubin Journal: Eur Respir J Date: 2019-01-24 Impact factor: 16.671
Authors: Robert A Lewis; Iain Armstrong; Carmel Bergbaum; Melanie J Brewis; John Cannon; Athanasios Charalampopoulos; A Colin Church; J Gerry Coghlan; Rachel J Davies; Konstantinos Dimopoulos; Charlie Elliot; J Simon R Gibbs; Wendy Gin-Sing; Gulam Haji; Abdul G Hameed; Luke S Howard; Martin K Johnson; Aleksander Kempny; David G Kiely; Francesco Lo Giudice; Colm McCabe; Andrew J Peacock; Oyinkansola Peleyeju; Joanna Pepke-Zaba; Gary Polwarth; Laura Price; Ian Sabroe; Benjamin E Schreiber; Karen Sheares; Dolores Taboada; A A Roger Thompson; Mark R Toshner; Ivy Wanjiku; S John Wort; Janelle Yorke; Robin Condliffe Journal: Eur Respir J Date: 2021-02-25 Impact factor: 16.671